Table of Contents
Why Some People Respond Differently to the Same Diet: Genetics, Inflammation, and Nutrient Metabolism
Abstract: People can respond differently to foods or alcohol because genes interact with metabolism, inflammation, medications, and lifestyle. This article explains ALDH2 in alcohol metabolism, ALOX15 in experimental omega-3 research, and why neither pathway predicts an individual cancer outcome.
During a holiday meal, one person may flush after a small glass of wine while another notices no obvious reaction. Two relatives can eat the same fatty fish or dessert yet show different triglyceride, glucose, digestive symptoms, or inflammatory markers.
Human metabolism is like a busy intersection, not a simple on-off switch. Genes help set the traffic lights, but food, alcohol, sleep, medications, hormones, physical activity, the gut environment, and existing disease influence how traffic moves.

Nutrigenomics: Why the Same Exposure Can Produce Different Biology
Nutrigenomics examines how nutrients and dietary patterns interact with gene expression and metabolic pathways. Nutrigenetics asks how inherited variants may influence an individual response to foods or nutrients.
A single genetic variant rarely explains an entire clinical outcome. It may alter the speed or efficiency of an enzyme, receptor, transporter, or signaling pathway. Its effect can then depend on dose, timing, tissue, other genes, and the person’s broader metabolic environment.
A changed metabolite is a biological mechanism; cancer development, prevention, or survival is a clinical endpoint requiring separate evidence.
Dr. Jimenez’s Unlocking Your Genetic Blueprint: The Inflammation Connection similarly places genetics beside biomarkers and lifestyle rather than treating DNA as a stand-alone answer.
ALDH2: A Clear Example From Alcohol Metabolism
After you consume ethanol, alcohol dehydrogenase converts it into acetaldehyde. Acetaldehyde is toxic and carcinogenic. Aldehyde dehydrogenase, particularly mitochondrial ALDH2, then helps convert acetaldehyde into acetate for further metabolism and elimination (National Institute on Alcohol Abuse and Alcoholism [NIAAA], n.d.).
What happens when ALDH2 activity is reduced?
The ALDH2 rs671 variant can reduce enzyme activity and is common in people of East Asian ancestry. When ALDH2 activity is low, acetaldehyde can accumulate after alcohol exposure. Individuals may develop facial flushing, warmth, rapid heartbeat, headache, or nausea.
The visible flush is not the concern. The important mechanism is slower acetaldehyde clearance and greater tissue exposure.
Population studies have linked low-activity ALDH2 variants, particularly among people who drink, with higher risks of certain upper digestive and aerodigestive cancers. Recent research also suggests ALDH2 status may interact with inherited DNA-repair variants (Tokunaga et al., 2026).
Still, ALDH2 genotype is not a cancer diagnosis. Risk also depends on alcohol dose, drinking pattern, smoking, age, other inherited variants, tissue susceptibility, and environmental factors. Genetics may modify exposure biology, but it does not make alcohol harmless or establish a personalized “safe” drinking threshold.
ALOX15: A Different Pathway Involving Fatty Acids
ALOX15 encodes 15-lipoxygenase-1, an enzyme that oxidizes polyunsaturated fatty acids. In experimental research, ALOX15 can help convert omega-3 fatty acids such as EPA and DHA into specialized lipid mediators involved in resolving inflammation.
Resolution is not simply “blocking inflammation.” It helps the body move from an active inflammatory response toward repair and homeostasis.
In 2025, researchers reported that intestinal ALOX15 expression changed how EPA and DHA affected colorectal tumor formation in mouse models. When researchers expressed human ALOX15 in intestinal epithelial cells, EPA and DHA generated more resolvins and were associated with reduced inflammatory signaling and tumor formation. Without that engineered expression, effects were more variable (Zuo et al., 2025).
That is compelling mechanistic science. It is not proof that an ALOX15 genetic test can tell a patient whether fish oil will prevent colorectal cancer.
Experimental muscle research adds another clue
A 2026 laboratory study found that several long-chain polyunsaturated fatty acids, including EPA and DHA, reduced colorectal-cancer-induced muscle-cell wasting in vitro through a pathway dependent on 15-lipoxygenase activity (Lu et al., 2026).
ALDH2 and ALOX15 Should Not Be Blended Together
ALDH2 primarily concerns aldehyde detoxification, including acetaldehyde clearance after alcohol exposure. ALOX15 participates in lipid oxidation and formation of signaling molecules derived from fatty acids.
One pathway may help explain differences in acetaldehyde exposure. The other may help explain why omega-3 fatty acids generate different downstream lipid mediators in certain tissues.
Neither gene is a universal nutrition score or a personal cancer forecast.
What Should an Evidence-Based Nutritional Assessment Measure?
Precision nutrition should begin with information that can change clinical decisions, not an oversized genetic report.
Depending on the clinical question, useful evaluation may include:
- Dietary history, alcohol pattern, medications, supplements, sleep, activity, and family history.
- Body composition and changes in weight or muscle mass.
- Glucose, hemoglobin A1c, insulin, lipids, and selected metabolic markers.
- Liver enzymes when alcohol exposure or metabolic dysfunction is relevant.
- Inflammatory biomarkers such as hs-CRP when clinically justified.
- Micronutrient testing when deficiency risk or dietary restriction supports it.
- Targeted genetic testing only when results have credible clinical interpretation.
Symptoms after a holiday meal do not automatically prove a food sensitivity. Broad unvalidated food-sensitivity panels can create confusion and unnecessary restriction. A careful history, validated testing when indicated, and supervised elimination or challenge strategies are more defensible.
The Multidisciplinary Clinical Model
At Dr. Alex Jimenez’s Injury Medical Chiropractic and Functional Medicine Clinic in El Paso, nutritional questions can be evaluated alongside physical function, metabolic biomarkers, injury recovery, and medical risk factors.
Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, bridges chiropractic care, advanced practice nursing, functional medicine, rehabilitation, and nutrition-focused assessment. Dr. Maria Guadalupe Cardenas, MD, a board-certified internal medicine physician with more than 40 years of experience, serves as Medical Director, Clinical Director, and Collaborative Physician. The clinic also includes nurse-practitioner expertise focused on soft-tissue injury.
This multidisciplinary structure makes the clinic unusual in El Paso and one of the few clinics in the area that combine medical oversight with chiropractic rehabilitation, laboratory evaluation, nutrition, acupuncture, electroacupuncture, and therapies.
The purpose is not to “treat a gene.” It connects history, examination, validated biomarkers, and medical oversight while tracking metabolic dysfunction, inflammation, nutrient status, gut health, oxidative stress, and relevant exposures.
For appropriate musculoskeletal conditions, screened chiropractic care, rehabilitation, and neurofunctional acupuncture or electroacupuncture may support pain relief, mobility, sleep, and nervous-system recovery. These supportive options do not prevent cancer or replace medical diagnosis or oncology care.
Genetics Can Inform Decisions Without Dictating Them
The strongest lesson from ALDH2 and ALOX15 is that identical exposures do not always create identical biology.
One person may clear acetaldehyde more slowly. Another may generate different lipid mediators from dietary fats. Someone else may have insulin resistance, liver disease, medication effects, poor sleep, or chronic inflammation that matters more than either pathway.
Patients should cross-check major dietary changes, high-dose supplements, alcohol concerns, and genetic interpretations with their medical team. Cancer, liver disease, active treatment, or complex medications require careful coordination.
Genetics can sharpen questions. Biomarkers can show what is happening now. Clinical follow-up determines whether an intervention is actually helping.
Coordinated next steps
If persistent symptoms, metabolic concerns, or confusing genetic results affect daily health, multidisciplinary evaluation can organize the evidence and support practical nutrition, safer movement, and coordinated care.
References
Lu, X., Maddipati, K. R., & Markworth, J. F. (2026). Long-chain polyunsaturated fatty acids mitigate in vitro skeletal muscle wasting induced by colorectal carcinoma cells via a 15-LOX-dependent pathway. bioRxiv.
National Institute on Alcohol Abuse and Alcoholism. (n.d.). Alcohol metabolism. U.S. Department of Health and Human Services.
Tokunaga, K., Koyanagi, Y. N., Iwashita, Y., Kasugai, Y., Otani, T., Yamamoto, S., Oze, I., Ito, S., Ito, N., Kobayashi, Y., Komori, K., Tanaka, T., Yamada, K., Abe, T., Tajika, M., Hanai, N., Usui, Y., Imoto, I., Momozawa, Y., … Matsuo, K. (2026). Joint effects of ALDH2 rs671 and pathogenic germline variants in DNA repair genes on risk of aerodigestive and gastrointestinal cancers. Cancer Epidemiology, Biomarkers & Prevention. Advance online publication. https://doi.org/10.1158/1055-9965.EPI-26-0629
Zuo, X., Kiyasu, Y., Liu, Y., Deguchi, Y., Liu, F., Moussalli, M., Tan, L., Wei, B., Wei, D., Yang, P., & Shureiqi, I. (2025). Colorectal 15-lipoxygenase-1 as a host factor determining the effects of eicosapentaenoic acid and docosahexaenoic acid on colorectal tumorigenesis in mice. Cellular and Molecular Gastroenterology and Hepatology, 19(12), 101607. https://doi.org/10.1016/j.jcmgh.2025.101607


Again, We Welcome You.
Comments are closed.